LONDON, January 15, 2018 /PRNewswire/ --
Forecasts by Drug Class (Antidopaminergics, Antipsychotics, Anticonvulsants, Antidepressants, Other) and Geography, with Analysis for Leading Drugs (Xenazine, Austedo, Clozapine, Haloperidol, Abilify), Leading Companies and Promising Pipeline Molecules
• Do you need definitive Huntington's Disease market data?
• Succinct Huntington's Disease market analysis?
• Technological insight?
• Actionable business recommendations?
(Logo: http://mma.prnewswire.com/media/523989/Visiongain_Logo.jpg )
Read on to discover how this definitive report can transform your own research and save you time.
The Global Huntington's Disease market shows immense potential to grow in the future, growing in line with some emerging trends. One such trend is the increasing strategic partnerships in a move to introduce or diversify product portfolios pertaining to drugs. Another trend is advances in biomedical sciences and introduction of nanotechnologies in the global pharmaceutical market, which are revolutionising the development of medicines.
Lastly, the study of the pathogenesis of disease at genetic and molecular level have led to the discovery of new targets for therapy and producing disease modifying drugs.
Report highlights
• 77 quantitative tables, charts, and graphs across 170 pages
• Global Huntington's Disease market outlook and analysis from 2018-2028
• Global Huntington's Disease submarket forecasts and analysis from 2018-2028
• Antidopaminergics
• Antipsychotics
• Anticonvulsants
• Antidepressants
• Other
• Regional and National Huntington's Disease market forecasts 2018-2028
• North America forecast 2018-2028
• US forecast 2018-2028
• Rest of North America forecast 2018-2028
• Europe forecast 2018-2028
• Germany forecast 2018-2028
• UK forecast 2018-2028
• France forecast 2018-2028
• Italy forecast 2018-2028
• Spain forecast 2018-2028
• Rest of Europe forecast 2018-2028
• Rest of World forecast 2018-2028
Key questions answered
• What does the future hold for the Pharmaceutical industry with regards to Huntington's Disease
• Where should you target your business strategy?
• Which applications should you focus upon?
• Which disruptive technologies should you invest in?
• Which companies should you form strategic alliances with?
• Which company is likely to success and why?
• What business models should you adopt?
• What industry trends should you be aware of?
Target audience
• Leading Pharmaceutical companies
• Suppliers
• Contractors
• Technologists
• R&D staff
• Consultants
• Analysts
• CEO's
• CIO's
• COO's
• Business development managers
• Investors
• Governments
• Agencies
• Banks
To request a report overview of this report please contact Sara Peerun at [email protected] (+44-(0)-20-733606100) or refer to our website: https://www.visiongain.com/Report/2099/Global-Huntington%E2%80%99s-Disease-Drugs-Market-Forecast-2018-2028
Companies Mentioned in the Report
Abbott Laboratories,Inc.,
Actavis
Aldagen
Allergan, Inc
Astra Zeneca
Auspex Pharmaceuticals Inc
Australian Securities Exchange
Bausch + Lomb
Baxter International, Inc.
BioMarin
Boston Scientific Corporation
BrainCells
Bristol-Meyers Squibb
Cardinal Health
Cephalon Inc.
CHDI Foundation
Defined Health
Dow AgroSciences
Eli Lilly
F. Hoffmann-La Roche AG
Fate Therapeutics
Forest Laboratories
Gedeon Richter
Genzyme
Germany Effects
Glaxo SmithKline
H. Lundbeck
Horizon Pharmaceutical LLC.
Hospira, Inc
InterMune
Intra-Cellular Therapies
Ionis Pharmaceuticals
Isis Pharmaceuticals
iZumi Bio.
Janssen Pharmaceuticals
Johnson & Johnson
KDL
Lundbeck Pharmaceuticals
Lupin
Luye Pharma
Marnac
Medtronic, Inc.
Merck Serono
MSI Methylation Sciences
Mylan Pharmaceuticals
Naurex
Neuroptix Corporation
Novartis AG
Omeros Corporation
Opko Health
Otsuka America Pharmaceutical, Inc.
To see a report overview please email Sara Peerun on [email protected]
SOURCE Visiongain
Share this article